

**Priority question for written answer P-000259/2021/rev.1
to the Commission**

Rule 138

Mihai Tudose (S&D)

Subject: Ensuring the necessary supply of COVID-19 vaccines

In theory, the agreements signed between the Commission and BioNTech-Pfizer and Moderna should ensure sufficient supplies of vaccine to immunise 380 million European citizens - over 80% of the EU's population. Unfortunately, this is a purely hypothetical scenario, given the problems that BioNTech-Pfizer is experiencing in meeting its commitments, with delivery delays seriously affecting Member States' supply chains and raising doubts as to whether the EU vaccination programme will be able to bring the pandemic emergency to a swift end.

In the meantime, immunisation of the most vulnerable population groups is already in full swing and the dithering and delays on the part of the producer are unacceptable, especially in view of the huge advances paid by the Commission last year on behalf of the EU Member States! Any disruption of supply will impact on human lives, and on the dependability and credibility of the vaccination programme.

Given that the Commission is responsible for the joint vaccine purchase system, what measures is it envisaging to guarantee the supply of vaccine in sufficient quantities for the mass immunisation of the EU population by the summer?